文献速递胃肠外科围术期管理与 ERAS

大型腹部手术患者的免疫营养:采用GRADE和CINeMA方法的综合系统评价与组件网络荟萃分析

Immunonutrition in patients who underwent major abdominal surgery: A comprehensive systematic review and component network metanalysis using GRADE and CINeMA approaches.
PubMed 文献 · Surgery · 2023-09-27

该系统评价与组件网络荟萃分析纳入87项随机临床试验共8375例大型腹部手术患者,评估免疫营养组分对结局的影响。围术期肠内/口服含精氨酸、谷氨酰胺和多不饱和脂肪酸的免疫营养与发病率降低相关(OR 0.32,95%CI 0.10-0.98),证据确定性中等。免疫营养对死亡率、感染并发症和住院时间的影响尚不明确。

要点

  • 围术期肠内/口服含精氨酸、谷氨酰胺和多不饱和脂肪酸的免疫营养可降低发病率(OR 0.32,95%CI 0.10-0.98),证据确定性中等。
  • 术后肠内免疫营养含RNA、精氨酸和多不饱和脂肪酸与死亡率降低相关(OR 59,95%CI 0.29-1.22),但证据确定性低。
  • 术后口服/肠内使用2种或3种免疫营养组分对降低发病率至关重要。

核心结论

  • 术后肠内/口服多种免疫营养组分可降低大型腹部手术患者的发病率。
  • 免疫营养对死亡率、感染性疾病和住院时间的影响尚不明确。

研究设计与样本

  • 系统检索关于大型腹部手术免疫营养的随机临床试验,采用频率随机效应组件网络荟萃分析,报告P评分及比值比或均数差与95%置信区间,并采用GRADE和CINeMA方法评价证据确定性。
  • 共纳入87项研究、8375例患者。

主要发现

  • 发病率方面,最佳方案为围术期肠内/口服含精氨酸、谷氨酰胺和多不饱和脂肪酸的免疫营养(OR 0.32,95%CI 0.10-0.98;P评分0.93),证据确定性中等。
  • 死亡率方面,术后肠内免疫营养含RNA、精氨酸和多不饱和脂肪酸可降低死亡率(OR 59,95%CI 0.29-1.22;P评分0.84),但证据确定性低。
  • 未观察到显著异质性或不一致性。
  • 住院时间和感染结局存在高异质性或网络荟萃分析不一致性的“风险”。
  • 组件分析证实,术后口服/肠内使用2种或3种组分对降低发病率至关重要。

关键数值与推荐

  • 发病率最佳方案:围术期肠内/口服精氨酸+谷氨酰胺+多不饱和脂肪酸,OR 0.32(95%CI 0.10-0.98),P评分0.93,证据确定性中等。
  • 死亡率方案:术后肠内RNA+精氨酸+多不饱和脂肪酸,OR 59(95%CI 0.29-1.22),P评分0.84,证据确定性低。
  • 术后口服/肠内使用2种或3种组分对降低发病率至关重要。

临床怎么用

  • 作者认为,术后肠内/口服多种免疫营养组分可降低大型腹部手术患者的发病率。
  • 免疫营养对死亡率、感染性疾病和住院时间的影响尚不明确。

局限性

  • 住院时间和感染结局存在高异质性或网络荟萃分析不一致性的“风险”。
  • 死亡率结局的证据确定性低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The benefits of immunonutrition in patients who underwent major abdominal surgery have been recently established, but the optimal combination of immunonutrients has remained unclear. The aim is to clarify this point. METHODS: A systematic search of randomized clinical trials about immunonutrition in major abdominal surgery was made. A frequentist random-effects component network meta-analysis was conducted, reporting the P score and odds ratio or mean difference with a 95% confidence interval. The best components and best plausible strategies were described. The critical endpoints were morbidity and mortality rates. The important endpoints were infectious complication rate and length of stay. RESULTS: The meta-analysis includes 87 studies and 8,375 patients. The best approach for morbidity rate, with a moderate grade of certainty, was the use of perioperative enteral/oral immunonutrition with arginine, glutamine, and polyunsaturated fatty acids (odds ratio 0.32; 0.10 to 0.98; P score of 0.93). The mortality rate was reduced by postoperative enteral immunonutrition with RNA, arginine, and polyunsaturated fatty acids (odds ratio 59; 0.29 to 1.22; P score 0.84) but with a low grade of certainty. No significant heterogeneity or incoherence is observed. The length of stay and infectious results are "at risk" for high heterogeneity or network meta-analysis incoherence. The component analysis confirmed that postoperative oral/enteral use of 2 or 3 components is crucial to reducing morbidity rate. CONCLUSION: The oral/enteral immunonutrition in the postoperative period, with multiple immunonutrients, can reduce the morbidity rate in patients undergoing major abdominal surgery. The effect of immunonutrition on mortality, infectious disease, and length of stay is unclear.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Ricci C, Serbassi F, Alberici L, et al. Immunonutrition in patients who underwent major abdominal surgery: A comprehensive systematic review and component network metanalysis using GRADE and CINeMA approaches. Surgery. 2023. PMID: 37775395. doi:10.1016/j.surg.2023.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。